nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—HTR2C—choroid plexus—intracranial aneurysm	0.045	0.0978	CbGeAlD
Sorafenib—MAPK15—brainstem—intracranial aneurysm	0.0195	0.0424	CbGeAlD
Sorafenib—MAPK15—medulla oblongata—intracranial aneurysm	0.0136	0.0296	CbGeAlD
Sorafenib—FLT1—artery—intracranial aneurysm	0.0136	0.0295	CbGeAlD
Sorafenib—KDR—artery—intracranial aneurysm	0.0115	0.0249	CbGeAlD
Sorafenib—CDKL3—brain—intracranial aneurysm	0.0095	0.0206	CbGeAlD
Sorafenib—CDKL2—brain—intracranial aneurysm	0.00869	0.0189	CbGeAlD
Sorafenib—MAPK15—brain—intracranial aneurysm	0.00782	0.017	CbGeAlD
Sorafenib—RAF1—brainstem—intracranial aneurysm	0.00575	0.0125	CbGeAlD
Sorafenib—MAPK11—cerebellum—intracranial aneurysm	0.00571	0.0124	CbGeAlD
Sorafenib—CDK7—cerebellum—intracranial aneurysm	0.00562	0.0122	CbGeAlD
Sorafenib—TAOK2—cerebellum—intracranial aneurysm	0.00557	0.0121	CbGeAlD
Sorafenib—BRAF—midbrain—intracranial aneurysm	0.0055	0.0119	CbGeAlD
Sorafenib—HIPK4—brain—intracranial aneurysm	0.00526	0.0114	CbGeAlD
Sorafenib—FGFR1—medulla oblongata—intracranial aneurysm	0.00512	0.0111	CbGeAlD
Sorafenib—MAP2K5—brainstem—intracranial aneurysm	0.00489	0.0106	CbGeAlD
Sorafenib—ZAK—cerebellum—intracranial aneurysm	0.00486	0.0105	CbGeAlD
Sorafenib—MAP3K7—medulla oblongata—intracranial aneurysm	0.00485	0.0105	CbGeAlD
Sorafenib—HIPK3—cerebellum—intracranial aneurysm	0.00475	0.0103	CbGeAlD
Sorafenib—MKNK2—medulla oblongata—intracranial aneurysm	0.0047	0.0102	CbGeAlD
Sorafenib—FGFR1—midbrain—intracranial aneurysm	0.00468	0.0102	CbGeAlD
Sorafenib—MKNK1—medulla oblongata—intracranial aneurysm	0.00464	0.0101	CbGeAlD
Sorafenib—MAPK11—brain—intracranial aneurysm	0.00464	0.0101	CbGeAlD
Sorafenib—RET—medulla oblongata—intracranial aneurysm	0.00458	0.00995	CbGeAlD
Sorafenib—CDK7—brain—intracranial aneurysm	0.00456	0.00991	CbGeAlD
Sorafenib—TAOK2—brain—intracranial aneurysm	0.00453	0.00983	CbGeAlD
Sorafenib—AURKC—brain—intracranial aneurysm	0.00449	0.00975	CbGeAlD
Sorafenib—TIE1—cerebellum—intracranial aneurysm	0.00444	0.00964	CbGeAlD
Sorafenib—MAP3K7—midbrain—intracranial aneurysm	0.00443	0.00962	CbGeAlD
Sorafenib—KIT—brainstem—intracranial aneurysm	0.00434	0.00941	CbGeAlD
Sorafenib—MKNK2—midbrain—intracranial aneurysm	0.00429	0.00932	CbGeAlD
Sorafenib—BRAF—cerebellum—intracranial aneurysm	0.00426	0.00924	CbGeAlD
Sorafenib—RALBP1—medulla oblongata—intracranial aneurysm	0.00424	0.00921	CbGeAlD
Sorafenib—MKNK1—midbrain—intracranial aneurysm	0.00424	0.0092	CbGeAlD
Sorafenib—RET—midbrain—intracranial aneurysm	0.00419	0.00909	CbGeAlD
Sorafenib—EPHA6—brain—intracranial aneurysm	0.00416	0.00903	CbGeAlD
Sorafenib—EPHX2—cerebellum—intracranial aneurysm	0.00407	0.00883	CbGeAlD
Sorafenib—FLT3—cerebellum—intracranial aneurysm	0.00404	0.00877	CbGeAlD
Sorafenib—FLT1—medulla oblongata—intracranial aneurysm	0.00404	0.00876	CbGeAlD
Sorafenib—RAF1—medulla oblongata—intracranial aneurysm	0.00401	0.00871	CbGeAlD
Sorafenib—EPHB6—medulla oblongata—intracranial aneurysm	0.00399	0.00866	CbGeAlD
Sorafenib—ZAK—brain—intracranial aneurysm	0.00394	0.00856	CbGeAlD
Sorafenib—RALBP1—midbrain—intracranial aneurysm	0.00388	0.00842	CbGeAlD
Sorafenib—HIPK3—brain—intracranial aneurysm	0.00386	0.00838	CbGeAlD
Sorafenib—MAP3K19—brain—intracranial aneurysm	0.00378	0.00821	CbGeAlD
Sorafenib—FLT1—midbrain—intracranial aneurysm	0.00369	0.00801	CbGeAlD
Sorafenib—RAF1—midbrain—intracranial aneurysm	0.00367	0.00796	CbGeAlD
Sorafenib—EPHB6—midbrain—intracranial aneurysm	0.00365	0.00791	CbGeAlD
Sorafenib—FGFR1—cerebellum—intracranial aneurysm	0.00362	0.00786	CbGeAlD
Sorafenib—TIE1—brain—intracranial aneurysm	0.00361	0.00783	CbGeAlD
Sorafenib—HTR2C—brainstem—intracranial aneurysm	0.00357	0.00775	CbGeAlD
Sorafenib—BRAF—brain—intracranial aneurysm	0.00346	0.00751	CbGeAlD
Sorafenib—MAP3K7—cerebellum—intracranial aneurysm	0.00343	0.00744	CbGeAlD
Sorafenib—MAP2K5—medulla oblongata—intracranial aneurysm	0.00341	0.00741	CbGeAlD
Sorafenib—KDR—medulla oblongata—intracranial aneurysm	0.00341	0.00741	CbGeAlD
Sorafenib—CSF1R—medulla oblongata—intracranial aneurysm	0.00333	0.00723	CbGeAlD
Sorafenib—MKNK2—cerebellum—intracranial aneurysm	0.00332	0.00721	CbGeAlD
Sorafenib—EPHX2—brain—intracranial aneurysm	0.00331	0.00718	CbGeAlD
Sorafenib—MKNK1—cerebellum—intracranial aneurysm	0.00328	0.00712	CbGeAlD
Sorafenib—RET—cerebellum—intracranial aneurysm	0.00324	0.00703	CbGeAlD
Sorafenib—KDR—midbrain—intracranial aneurysm	0.00312	0.00677	CbGeAlD
Sorafenib—MAP2K5—midbrain—intracranial aneurysm	0.00312	0.00677	CbGeAlD
Sorafenib—CSF1R—midbrain—intracranial aneurysm	0.00304	0.00661	CbGeAlD
Sorafenib—KIT—medulla oblongata—intracranial aneurysm	0.00302	0.00656	CbGeAlD
Sorafenib—RALBP1—cerebellum—intracranial aneurysm	0.003	0.00651	CbGeAlD
Sorafenib—FLT4—brain—intracranial aneurysm	0.00298	0.00647	CbGeAlD
Sorafenib—PDGFRB—medulla oblongata—intracranial aneurysm	0.00295	0.00641	CbGeAlD
Sorafenib—FGFR1—brain—intracranial aneurysm	0.00294	0.00638	CbGeAlD
Sorafenib—FLT1—cerebellum—intracranial aneurysm	0.00285	0.00619	CbGeAlD
Sorafenib—RAF1—cerebellum—intracranial aneurysm	0.00284	0.00616	CbGeAlD
Sorafenib—EPHB6—cerebellum—intracranial aneurysm	0.00282	0.00612	CbGeAlD
Sorafenib—MAP3K7—brain—intracranial aneurysm	0.00278	0.00604	CbGeAlD
Sorafenib—KIT—midbrain—intracranial aneurysm	0.00276	0.006	CbGeAlD
Sorafenib—STK10—cerebellum—intracranial aneurysm	0.0027	0.00586	CbGeAlD
Sorafenib—PDGFRB—midbrain—intracranial aneurysm	0.0027	0.00586	CbGeAlD
Sorafenib—MKNK2—brain—intracranial aneurysm	0.0027	0.00586	CbGeAlD
Sorafenib—PDGFRA—cerebellum—intracranial aneurysm	0.00267	0.0058	CbGeAlD
Sorafenib—MKNK1—brain—intracranial aneurysm	0.00266	0.00578	CbGeAlD
Sorafenib—RET—brain—intracranial aneurysm	0.00263	0.00571	CbGeAlD
Sorafenib—HTR2C—medulla oblongata—intracranial aneurysm	0.00249	0.0054	CbGeAlD
Sorafenib—RALBP1—brain—intracranial aneurysm	0.00244	0.00529	CbGeAlD
Sorafenib—KDR—cerebellum—intracranial aneurysm	0.00241	0.00524	CbGeAlD
Sorafenib—MAP2K5—cerebellum—intracranial aneurysm	0.00241	0.00524	CbGeAlD
Sorafenib—CSF1R—cerebellum—intracranial aneurysm	0.00235	0.00511	CbGeAlD
Sorafenib—FLT1—brain—intracranial aneurysm	0.00232	0.00503	CbGeAlD
Sorafenib—RAF1—brain—intracranial aneurysm	0.0023	0.005	CbGeAlD
Sorafenib—EPHB6—brain—intracranial aneurysm	0.00229	0.00497	CbGeAlD
Sorafenib—HTR2C—midbrain—intracranial aneurysm	0.00228	0.00494	CbGeAlD
Sorafenib—STK10—brain—intracranial aneurysm	0.00219	0.00476	CbGeAlD
Sorafenib—PDGFRA—brain—intracranial aneurysm	0.00217	0.00471	CbGeAlD
Sorafenib—KIT—cerebellum—intracranial aneurysm	0.00214	0.00464	CbGeAlD
Sorafenib—PDGFRB—cerebellum—intracranial aneurysm	0.00209	0.00453	CbGeAlD
Sorafenib—MAP2K5—brain—intracranial aneurysm	0.00196	0.00425	CbGeAlD
Sorafenib—KDR—brain—intracranial aneurysm	0.00196	0.00425	CbGeAlD
Sorafenib—CSF1R—brain—intracranial aneurysm	0.00191	0.00415	CbGeAlD
Sorafenib—KIT—brain—intracranial aneurysm	0.00174	0.00377	CbGeAlD
Sorafenib—PDGFRB—brain—intracranial aneurysm	0.0017	0.00368	CbGeAlD
Sorafenib—ABCG2—medulla oblongata—intracranial aneurysm	0.00166	0.0036	CbGeAlD
Sorafenib—CYP2D6—brainstem—intracranial aneurysm	0.00163	0.00354	CbGeAlD
Sorafenib—ABCG2—midbrain—intracranial aneurysm	0.00152	0.00329	CbGeAlD
Sorafenib—HTR2C—brain—intracranial aneurysm	0.00143	0.0031	CbGeAlD
Sorafenib—ABCC4—brain—intracranial aneurysm	0.00135	0.00293	CbGeAlD
Sorafenib—HTR2B—brain—intracranial aneurysm	0.00134	0.00292	CbGeAlD
Sorafenib—ABCG2—cerebellum—intracranial aneurysm	0.00117	0.00255	CbGeAlD
Sorafenib—CYP2C8—brain—intracranial aneurysm	0.00098	0.00213	CbGeAlD
Sorafenib—ABCG2—brain—intracranial aneurysm	0.000953	0.00207	CbGeAlD
Sorafenib—CYP2B6—brain—intracranial aneurysm	0.000879	0.00191	CbGeAlD
Sorafenib—ABCB1—medulla oblongata—intracranial aneurysm	0.000818	0.00178	CbGeAlD
Sorafenib—CYP2D6—cerebellum—intracranial aneurysm	0.000804	0.00175	CbGeAlD
Sorafenib—ABCB1—midbrain—intracranial aneurysm	0.000748	0.00162	CbGeAlD
Sorafenib—CYP2D6—brain—intracranial aneurysm	0.000653	0.00142	CbGeAlD
Sorafenib—ABCB1—cerebellum—intracranial aneurysm	0.000579	0.00126	CbGeAlD
Sorafenib—MAP3K7—Innate Immune System—CTSB—intracranial aneurysm	0.000518	0.000961	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—CTSS—intracranial aneurysm	0.000517	0.000959	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CST3—intracranial aneurysm	0.000515	0.000954	CbGpPWpGaD
Sorafenib—EPHA6—Developmental Biology—MMP2—intracranial aneurysm	0.000513	0.000951	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—NCF1—intracranial aneurysm	0.000513	0.000951	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—CTSK—intracranial aneurysm	0.000513	0.00095	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—NCF1—intracranial aneurysm	0.000504	0.000935	CbGpPWpGaD
Sorafenib—FGFR1—Signaling by SCF-KIT—MMP9—intracranial aneurysm	0.000503	0.000932	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling by SCF-KIT—MMP9—intracranial aneurysm	0.000501	0.00093	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—CTSB—intracranial aneurysm	0.000498	0.000923	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—CTSB—intracranial aneurysm	0.000498	0.000923	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—CTSS—intracranial aneurysm	0.000496	0.000921	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—NCF1—intracranial aneurysm	0.000495	0.000918	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—NCF1—intracranial aneurysm	0.000495	0.000918	CbGpPWpGaD
Sorafenib—HTR2B—GPCR ligand binding—EDNRA—intracranial aneurysm	0.000492	0.000912	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—CTSB—intracranial aneurysm	0.000492	0.000912	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—CTSB—intracranial aneurysm	0.000491	0.000909	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—EDNRA—intracranial aneurysm	0.000484	0.000898	CbGpPWpGaD
Sorafenib—CDK7—Disease—CST3—intracranial aneurysm	0.000484	0.000897	CbGpPWpGaD
Sorafenib—ABCC4—Hemostasis—TIMP1—intracranial aneurysm	0.000476	0.000883	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—EDNRA—intracranial aneurysm	0.000476	0.000883	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—CTSK—intracranial aneurysm	0.000476	0.000882	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—CTSB—intracranial aneurysm	0.000472	0.000876	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—CTSB—intracranial aneurysm	0.000471	0.000873	CbGpPWpGaD
Sorafenib—ABCB1—brain—intracranial aneurysm	0.00047	0.00102	CbGeAlD
Sorafenib—FGFR1—Adaptive Immune System—NCF1—intracranial aneurysm	0.00047	0.000871	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—NCF1—intracranial aneurysm	0.000469	0.000869	CbGpPWpGaD
Sorafenib—KDR—Axon guidance—MMP2—intracranial aneurysm	0.000467	0.000866	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—SLC25A16—intracranial aneurysm	0.000462	0.000856	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—SLC25A16—intracranial aneurysm	0.000458	0.000849	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—CTSK—intracranial aneurysm	0.000457	0.000847	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by SCF-KIT—MMP9—intracranial aneurysm	0.000452	0.000837	CbGpPWpGaD
Sorafenib—RAF1—EGF/EGFR Signaling Pathway—NOS3—intracranial aneurysm	0.000449	0.000832	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—CTSB—intracranial aneurysm	0.000442	0.000819	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—CTSS—intracranial aneurysm	0.000439	0.000815	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—ASAH1—intracranial aneurysm	0.000426	0.000791	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—CTSB—intracranial aneurysm	0.000424	0.000787	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—NCF1—intracranial aneurysm	0.000422	0.000783	CbGpPWpGaD
Sorafenib—CDK7—Disease—NCF1—intracranial aneurysm	0.00042	0.00078	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—NCF1—intracranial aneurysm	0.000418	0.000775	CbGpPWpGaD
Sorafenib—KDR—Extracellular matrix organization—MMP9—intracranial aneurysm	0.000414	0.000767	CbGpPWpGaD
Sorafenib—EPHB6—Developmental Biology—MMP9—intracranial aneurysm	0.00041	0.00076	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—CTSK—intracranial aneurysm	0.000404	0.00075	CbGpPWpGaD
Sorafenib—RAF1—Signaling by SCF-KIT—MMP9—intracranial aneurysm	0.000403	0.000746	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—TIMP1—intracranial aneurysm	0.000401	0.000743	CbGpPWpGaD
Sorafenib—HTR2C—GPCR ligand binding—EDNRA—intracranial aneurysm	0.000397	0.000736	CbGpPWpGaD
Sorafenib—KIT—Immune System—CTSS—intracranial aneurysm	0.000396	0.000735	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—CTSS—intracranial aneurysm	0.000396	0.000735	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—EDNRA—intracranial aneurysm	0.000395	0.000732	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—CTSB—intracranial aneurysm	0.000394	0.00073	CbGpPWpGaD
Sorafenib—EPHA6—Developmental Biology—MMP9—intracranial aneurysm	0.000386	0.000715	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—ASAH1—intracranial aneurysm	0.000381	0.000706	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—CTSB—intracranial aneurysm	0.000378	0.000701	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—NCF1—intracranial aneurysm	0.000376	0.000698	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—NCF1—intracranial aneurysm	0.000376	0.000698	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—CTSS—intracranial aneurysm	0.000376	0.000697	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CTSS—intracranial aneurysm	0.000375	0.000695	CbGpPWpGaD
Sorafenib—MAPK11—Innate Immune System—AGER—intracranial aneurysm	0.000371	0.000688	CbGpPWpGaD
Sorafenib—KIT—Immune System—CTSK—intracranial aneurysm	0.000365	0.000676	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—CTSK—intracranial aneurysm	0.000365	0.000676	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—ASAH1—intracranial aneurysm	0.000361	0.000669	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—ASAH1—intracranial aneurysm	0.000361	0.000669	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—EDNRA—intracranial aneurysm	0.000355	0.000659	CbGpPWpGaD
Sorafenib—KDR—Axon guidance—MMP9—intracranial aneurysm	0.000351	0.000651	CbGpPWpGaD
Sorafenib—BRAF—Disease—CST3—intracranial aneurysm	0.00035	0.000649	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—ASAH1—intracranial aneurysm	0.000347	0.000643	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—CTSK—intracranial aneurysm	0.000346	0.000642	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CTSK—intracranial aneurysm	0.000345	0.00064	CbGpPWpGaD
Sorafenib—FGFR1—Axon guidance—MMP2—intracranial aneurysm	0.000344	0.000637	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—SLC25A16—intracranial aneurysm	0.000339	0.000628	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CTSS—intracranial aneurysm	0.000338	0.000626	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—CTSB—intracranial aneurysm	0.000335	0.000621	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—AGER—intracranial aneurysm	0.000334	0.00062	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—AGER—intracranial aneurysm	0.000334	0.00062	CbGpPWpGaD
Sorafenib—KDR—Developmental Biology—MMP2—intracranial aneurysm	0.000333	0.000618	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—NCF1—intracranial aneurysm	0.000333	0.000617	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—SLC25A16—intracranial aneurysm	0.000331	0.000614	CbGpPWpGaD
Sorafenib—KIT—Disease—CST3—intracranial aneurysm	0.000319	0.000591	CbGpPWpGaD
Sorafenib—HTR2B—Class A/1 (Rhodopsin-like receptors)—CCL2—intracranial aneurysm	0.000318	0.00059	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—AGER—intracranial aneurysm	0.000317	0.000589	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—AGER—intracranial aneurysm	0.000317	0.000587	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CTSK—intracranial aneurysm	0.000311	0.000577	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—ASAH1—intracranial aneurysm	0.000306	0.000567	CbGpPWpGaD
Sorafenib—BRAF—Disease—NCF1—intracranial aneurysm	0.000305	0.000565	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—ASAH1—intracranial aneurysm	0.000303	0.000562	CbGpPWpGaD
Sorafenib—FGFR1—Disease—CST3—intracranial aneurysm	0.000303	0.000561	CbGpPWpGaD
Sorafenib—KIT—Immune System—CTSB—intracranial aneurysm	0.000302	0.00056	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—CTSB—intracranial aneurysm	0.000302	0.00056	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—CST3—intracranial aneurysm	0.000302	0.00056	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CTSS—intracranial aneurysm	0.000301	0.000558	CbGpPWpGaD
Sorafenib—KIT—Immune System—NCF1—intracranial aneurysm	0.0003	0.000557	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—NCF1—intracranial aneurysm	0.0003	0.000557	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—ASAH1—intracranial aneurysm	0.000297	0.00055	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—SLC25A16—intracranial aneurysm	0.000287	0.000531	CbGpPWpGaD
Sorafenib—MAPK11—Developmental Biology—MMP2—intracranial aneurysm	0.000287	0.000531	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—CTSB—intracranial aneurysm	0.000286	0.000531	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CTSB—intracranial aneurysm	0.000286	0.00053	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—AGER—intracranial aneurysm	0.000285	0.000529	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—NCF1—intracranial aneurysm	0.000285	0.000528	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—NCF1—intracranial aneurysm	0.000284	0.000527	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—EDNRA—intracranial aneurysm	0.000278	0.000515	CbGpPWpGaD
Sorafenib—KIT—Disease—NCF1—intracranial aneurysm	0.000277	0.000514	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CTSK—intracranial aneurysm	0.000277	0.000514	CbGpPWpGaD
Sorafenib—RAF1—Axon guidance—MMP2—intracranial aneurysm	0.000275	0.00051	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—CST3—intracranial aneurysm	0.000272	0.000504	CbGpPWpGaD
Sorafenib—FGFR1—Disease—NCF1—intracranial aneurysm	0.000263	0.000488	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—NCF1—intracranial aneurysm	0.000262	0.000487	CbGpPWpGaD
Sorafenib—FGFR1—Axon guidance—MMP9—intracranial aneurysm	0.000258	0.000479	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CTSB—intracranial aneurysm	0.000257	0.000477	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—NCF1—intracranial aneurysm	0.000257	0.000476	CbGpPWpGaD
Sorafenib—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCL2—intracranial aneurysm	0.000257	0.000476	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—NCF1—intracranial aneurysm	0.000256	0.000475	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—SLC25A16—intracranial aneurysm	0.000256	0.000474	CbGpPWpGaD
Sorafenib—EPHX2—Metabolism—NOS3—intracranial aneurysm	0.000254	0.000471	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—AGER—intracranial aneurysm	0.000254	0.000471	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—EDNRA—intracranial aneurysm	0.000252	0.000468	CbGpPWpGaD
Sorafenib—KDR—Developmental Biology—MMP9—intracranial aneurysm	0.000251	0.000464	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—NCF1—intracranial aneurysm	0.00025	0.000464	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—SLC25A16—intracranial aneurysm	0.00025	0.000463	CbGpPWpGaD
Sorafenib—MKNK1—Disease—NOS3—intracranial aneurysm	0.000248	0.000459	CbGpPWpGaD
Sorafenib—FGFR1—Developmental Biology—MMP2—intracranial aneurysm	0.000245	0.000455	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—EDNRA—intracranial aneurysm	0.000243	0.00045	CbGpPWpGaD
Sorafenib—HTR2B—GPCR ligand binding—CCL2—intracranial aneurysm	0.000242	0.000449	CbGpPWpGaD
Sorafenib—RAF1—Disease—CST3—intracranial aneurysm	0.000242	0.000449	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—CCL2—intracranial aneurysm	0.000239	0.000442	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—EDNRA—intracranial aneurysm	0.000236	0.000438	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—NCF1—intracranial aneurysm	0.000236	0.000438	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—EDNRA—intracranial aneurysm	0.000236	0.000437	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—SLC25A16—intracranial aneurysm	0.000235	0.000436	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—CCL2—intracranial aneurysm	0.000235	0.000435	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—SLC25A16—intracranial aneurysm	0.000233	0.000433	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CTSB—intracranial aneurysm	0.000229	0.000425	CbGpPWpGaD
Sorafenib—RAF1—Immune System—NCF1—intracranial aneurysm	0.000228	0.000423	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ASAH1—intracranial aneurysm	0.000224	0.000416	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—EDNRA—intracranial aneurysm	0.000224	0.000416	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ASAH1—intracranial aneurysm	0.000219	0.000406	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—AGER—intracranial aneurysm	0.000216	0.000401	CbGpPWpGaD
Sorafenib—MAPK11—Developmental Biology—MMP9—intracranial aneurysm	0.000215	0.000399	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—NCF1—intracranial aneurysm	0.000215	0.000399	CbGpPWpGaD
Sorafenib—ABCC4—Hemostasis—NOS3—intracranial aneurysm	0.000215	0.000398	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—NCF1—intracranial aneurysm	0.000213	0.000395	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—NOS3—intracranial aneurysm	0.000213	0.000394	CbGpPWpGaD
Sorafenib—RAF1—Disease—NCF1—intracranial aneurysm	0.000211	0.000391	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—NOS3—intracranial aneurysm	0.000209	0.000388	CbGpPWpGaD
Sorafenib—RAF1—Axon guidance—MMP9—intracranial aneurysm	0.000207	0.000384	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—EDNRA—intracranial aneurysm	0.000204	0.000378	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—EDNRA—intracranial aneurysm	0.000203	0.000377	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—EDNRA—intracranial aneurysm	0.000201	0.000373	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—SLC25A16—intracranial aneurysm	0.000199	0.00037	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—MMP2—intracranial aneurysm	0.000196	0.000364	CbGpPWpGaD
Sorafenib—HTR2C—GPCR ligand binding—CCL2—intracranial aneurysm	0.000196	0.000363	CbGpPWpGaD
Sorafenib—KIT—Immune System—AGER—intracranial aneurysm	0.000195	0.000361	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—AGER—intracranial aneurysm	0.000195	0.000361	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—CCL2—intracranial aneurysm	0.000194	0.000361	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—NCF1—intracranial aneurysm	0.000194	0.00036	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—NCF1—intracranial aneurysm	0.000194	0.00036	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ASAH1—intracranial aneurysm	0.00019	0.000352	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—AGER—intracranial aneurysm	0.000185	0.000343	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—AGER—intracranial aneurysm	0.000184	0.000342	CbGpPWpGaD
Sorafenib—FGFR1—Developmental Biology—MMP9—intracranial aneurysm	0.000184	0.000342	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—NCF1—intracranial aneurysm	0.000184	0.000342	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—NCF1—intracranial aneurysm	0.000184	0.000341	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—EDNRA—intracranial aneurysm	0.000183	0.00034	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—EDNRA—intracranial aneurysm	0.000183	0.00034	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—NOS3—intracranial aneurysm	0.000181	0.000335	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—CCL2—intracranial aneurysm	0.000175	0.000325	CbGpPWpGaD
Sorafenib—CDK7—Disease—NOS3—intracranial aneurysm	0.000174	0.000323	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—EDNRA—intracranial aneurysm	0.000174	0.000323	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—EDNRA—intracranial aneurysm	0.000174	0.000322	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—NOS3—intracranial aneurysm	0.000173	0.000321	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—MMP9—intracranial aneurysm	0.000171	0.000316	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ASAH1—intracranial aneurysm	0.000169	0.000314	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—MMP9—intracranial aneurysm	0.000168	0.000311	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—AGER—intracranial aneurysm	0.000166	0.000308	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NCF1—intracranial aneurysm	0.000166	0.000307	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ASAH1—intracranial aneurysm	0.000165	0.000307	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NCF1—intracranial aneurysm	0.000158	0.000293	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—EDNRA—intracranial aneurysm	0.000156	0.00029	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—NOS3—intracranial aneurysm	0.000156	0.000289	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ASAH1—intracranial aneurysm	0.000156	0.000289	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ASAH1—intracranial aneurysm	0.000155	0.000287	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SLC25A16—intracranial aneurysm	0.000154	0.000285	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EDNRA—intracranial aneurysm	0.000149	0.000276	CbGpPWpGaD
Sorafenib—RAF1—Immune System—AGER—intracranial aneurysm	0.000148	0.000275	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—MMP9—intracranial aneurysm	0.000148	0.000274	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NCF1—intracranial aneurysm	0.000148	0.000274	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EDNRA—intracranial aneurysm	0.000139	0.000258	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—MMP9—intracranial aneurysm	0.000139	0.000258	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ASAH1—intracranial aneurysm	0.000132	0.000245	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NCF1—intracranial aneurysm	0.000127	0.000236	CbGpPWpGaD
Sorafenib—BRAF—Disease—NOS3—intracranial aneurysm	0.000126	0.000234	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—MMP9—intracranial aneurysm	0.000125	0.000232	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—CCL2—intracranial aneurysm	0.000124	0.000231	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EDNRA—intracranial aneurysm	0.00012	0.000223	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—CCL2—intracranial aneurysm	0.00012	0.000222	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—CCL2—intracranial aneurysm	0.000117	0.000216	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—CCL2—intracranial aneurysm	0.000116	0.000216	CbGpPWpGaD
Sorafenib—KIT—Disease—NOS3—intracranial aneurysm	0.000115	0.000213	CbGpPWpGaD
Sorafenib—FGFR1—Disease—NOS3—intracranial aneurysm	0.000109	0.000202	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—NOS3—intracranial aneurysm	0.000109	0.000202	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—NOS3—intracranial aneurysm	0.000107	0.000198	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—NOS3—intracranial aneurysm	0.000104	0.000193	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ASAH1—intracranial aneurysm	0.000102	0.000189	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—CCL2—intracranial aneurysm	0.0001	0.000186	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CCL2—intracranial aneurysm	0.0001	0.000186	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CCL2—intracranial aneurysm	9.92e-05	0.000184	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—NOS3—intracranial aneurysm	9.81e-05	0.000182	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CCL2—intracranial aneurysm	9.03e-05	0.000167	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CCL2—intracranial aneurysm	9.03e-05	0.000167	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—NOS3—intracranial aneurysm	8.93e-05	0.000166	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—NOS3—intracranial aneurysm	8.85e-05	0.000164	CbGpPWpGaD
Sorafenib—RAF1—Disease—NOS3—intracranial aneurysm	8.74e-05	0.000162	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CCL2—intracranial aneurysm	8.57e-05	0.000159	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CCL2—intracranial aneurysm	8.55e-05	0.000159	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—MMP9—intracranial aneurysm	8.55e-05	0.000159	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—MMP9—intracranial aneurysm	8.33e-05	0.000154	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—NOS3—intracranial aneurysm	8.05e-05	0.000149	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—NOS3—intracranial aneurysm	8.05e-05	0.000149	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CCL2—intracranial aneurysm	7.7e-05	0.000143	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—NOS3—intracranial aneurysm	7.64e-05	0.000142	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—NOS3—intracranial aneurysm	7.62e-05	0.000141	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—NOS3—intracranial aneurysm	7.52e-05	0.00014	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—NOS3—intracranial aneurysm	7.52e-05	0.00014	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CCL2—intracranial aneurysm	7.35e-05	0.000136	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MMP9—intracranial aneurysm	7.16e-05	0.000133	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MMP9—intracranial aneurysm	7.1e-05	0.000132	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCL2—intracranial aneurysm	6.87e-05	0.000127	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NOS3—intracranial aneurysm	6.87e-05	0.000127	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NOS3—intracranial aneurysm	6.55e-05	0.000121	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MMP9—intracranial aneurysm	6.46e-05	0.00012	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MMP9—intracranial aneurysm	6.46e-05	0.00012	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—NOS3—intracranial aneurysm	6.38e-05	0.000118	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—NOS3—intracranial aneurysm	6.33e-05	0.000117	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MMP9—intracranial aneurysm	6.13e-05	0.000114	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NOS3—intracranial aneurysm	6.12e-05	0.000113	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MMP9—intracranial aneurysm	6.11e-05	0.000113	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCL2—intracranial aneurysm	5.93e-05	0.00011	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MMP9—intracranial aneurysm	5.51e-05	0.000102	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NOS3—intracranial aneurysm	5.28e-05	9.8e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MMP9—intracranial aneurysm	5.25e-05	9.74e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MMP9—intracranial aneurysm	4.91e-05	9.1e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—NOS3—intracranial aneurysm	4.68e-05	8.68e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—NOS3—intracranial aneurysm	4.57e-05	8.48e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MMP9—intracranial aneurysm	4.24e-05	7.86e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—NOS3—intracranial aneurysm	3.96e-05	7.35e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—NOS3—intracranial aneurysm	3.54e-05	6.56e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—NOS3—intracranial aneurysm	3.45e-05	6.4e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—NOS3—intracranial aneurysm	3.25e-05	6.03e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—NOS3—intracranial aneurysm	3.22e-05	5.98e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—NOS3—intracranial aneurysm	2.76e-05	5.11e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NOS3—intracranial aneurysm	2.13e-05	3.94e-05	CbGpPWpGaD
